FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4315703046> ?p ?o ?g. }

• W4315703046 endingPage "e287" @default.
• W4315703046 startingPage "e287" @default.
• W4315703046 abstract "Background: Human adrenomedullin (hAM) is a hypotensive peptide hormone with strong anti-inflammatory effects. AM consists of 52 amino acid residues with an amidated C-terminus and a ring structure formed by intramolecular disulfide bonds. Both of these structures are necessary for binding to receptors and to exert their biological functions. AM has also shown therapeutic effects in various animal disease models, including inflammatory bowel disease, ischemic heart disease, sepsis and stroke. However, the short half-life of native AM in the blood required continuous administration for treatment. To solve this, we have developed four human IgG1 and IgG4 Fc fusion proteins containing full-length human AM or AM(6–52). Methods: Recombinant Fc-AM derivatives were generated using mammalian cells. After that, we tested the biological activities of Fc-fusion AMs (Fc-AMs) to stimulate the intracellular accumulation of cAMP in HEK-293 cells stably expressing the AM1 receptor. Next, we compared IgG1-AM (6–52) and IgG4-AM (6–52) concentrations in the peripheral blood and tissues of rats after subcutaneous injection. In addition, the antihypertensive effect of Fc-AM was examined on spontaneously hypertensive rats (SHRs) which were given high salt diets. Results: We have developed four Fc-AMs, which are long-acting AM derivatives in mammalian cells. Fc-AMs produced in mammalian cells do not require refolding or amidation. Indeed, Fc-AMs could be measured by mAM assay, which recognizes the amidated form, indicating that Fc-AMs produced in mammalian cells were amidated. Fc-AMs, generated in a mammalian cell production system can therefore easily be produced in large amounts with few purification steps. The Fc-AMs stimulated intracellular cAMP production in cultured cells stably expressing the AM type I receptor in vitro. Fc-AM (6–52) induced higher cAMP levels for the receptor than Fc-AM. The pharmacokinetic study was performed using N-terminal deficient AM derivatives, which have strong receptor binding ability. Sufficient concentrations of IgG1-AM (6–52) and IgG4-AM (6–52) were observed in blood 14 days after a single subcutaneous administration. Tissue transfer to the kidney and small intestine was observed after administration of IgG1-AM (6–52) or IgG4-AM (6–52) to rats. In addition, the single subcutaneous administration of IgG4-AM (6–52) suppressed the increase in blood pressure in SHRs which were loaded with high salt diets. Conclusion: Fc-AM produced from mammalian cells is easily prepared and seems to be an effective new therapeutic agent for hypertension." @default.
• W4315703046 created "2023-01-12" @default.
• W4315703046 creator A5048075263 @default.
• W4315703046 creator A5053241809 @default.
• W4315703046 creator A5063426384 @default.
• W4315703046 creator A5088387742 @default.
• W4315703046 date "2023-01-01" @default.
• W4315703046 modified "2023-10-02" @default.
• W4315703046 title "PS-BPB09-2: DEVELOPMENT OF LONG-ACTING HUMAN ADRENOMEDULLIN FC FUSION PROTEINS" @default.
• W4315703046 doi "https://doi.org/10.1097/01.hjh.0000915656.89376.1a" @default.
• W4315703046 hasPublicationYear "2023" @default.
• W4315703046 type Work @default.
• W4315703046 citedByCount "0" @default.
• W4315703046 crossrefType "journal-article" @default.
• W4315703046 hasAuthorship W4315703046A5048075263 @default.
• W4315703046 hasAuthorship W4315703046A5053241809 @default.
• W4315703046 hasAuthorship W4315703046A5063426384 @default.
• W4315703046 hasAuthorship W4315703046A5088387742 @default.
• W4315703046 hasBestOaLocation W43157030461 @default.
• W4315703046 hasConcept C104317684 @default.
• W4315703046 hasConcept C123894998 @default.
• W4315703046 hasConcept C126322002 @default.
• W4315703046 hasConcept C159654299 @default.
• W4315703046 hasConcept C170493617 @default.
• W4315703046 hasConcept C203014093 @default.
• W4315703046 hasConcept C2777152744 @default.
• W4315703046 hasConcept C2778384902 @default.
• W4315703046 hasConcept C40767141 @default.
• W4315703046 hasConcept C55493867 @default.
• W4315703046 hasConcept C71924100 @default.
• W4315703046 hasConcept C86803240 @default.
• W4315703046 hasConcept C98274493 @default.
• W4315703046 hasConceptScore W4315703046C104317684 @default.
• W4315703046 hasConceptScore W4315703046C123894998 @default.
• W4315703046 hasConceptScore W4315703046C126322002 @default.
• W4315703046 hasConceptScore W4315703046C159654299 @default.
• W4315703046 hasConceptScore W4315703046C170493617 @default.
• W4315703046 hasConceptScore W4315703046C203014093 @default.
• W4315703046 hasConceptScore W4315703046C2777152744 @default.
• W4315703046 hasConceptScore W4315703046C2778384902 @default.
• W4315703046 hasConceptScore W4315703046C40767141 @default.
• W4315703046 hasConceptScore W4315703046C55493867 @default.
• W4315703046 hasConceptScore W4315703046C71924100 @default.
• W4315703046 hasConceptScore W4315703046C86803240 @default.
• W4315703046 hasConceptScore W4315703046C98274493 @default.
• W4315703046 hasIssue "Suppl 1" @default.
• W4315703046 hasLocation W43157030461 @default.
• W4315703046 hasLocation W43157030462 @default.
• W4315703046 hasOpenAccess W4315703046 @default.
• W4315703046 hasPrimaryLocation W43157030461 @default.
• W4315703046 hasRelatedWork W1983741712 @default.
• W4315703046 hasRelatedWork W1999148898 @default.
• W4315703046 hasRelatedWork W2053300940 @default.
• W4315703046 hasRelatedWork W2063308606 @default.
• W4315703046 hasRelatedWork W2099308424 @default.
• W4315703046 hasRelatedWork W2379672687 @default.
• W4315703046 hasRelatedWork W2408010109 @default.
• W4315703046 hasRelatedWork W2590644762 @default.
• W4315703046 hasRelatedWork W2783073608 @default.
• W4315703046 hasRelatedWork W4318822982 @default.
• W4315703046 hasVolume "41" @default.
• W4315703046 isParatext "false" @default.
• W4315703046 isRetracted "false" @default.
• W4315703046 workType "article" @default.